The role of indoleamine 2,3 dioxygenase in beneficial effects of stem cells in hind limb ischemia reperfusion injury

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Masoumy, Mohamad ^a   Yu, Jack ^a   Liu, Jun Yao ^b   Yanasak, Nathan ^a   Middleton, Christopher ^a   Lamoke, Folami ^a   Mozaffari, Mahmood S ^b   Baban, Babak ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b AUGUSTA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HINDLIMB; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KNOCKOUT MOUSE; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL MOBILITY; REPERFUSION INJURY; VIDEORECORDING; WILD TYPE; ANIMAL; C57BL MOUSE; CELL CULTURE; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; STEM CELL;

ANIMALS; CELLS, CULTURED; FLOW CYTOMETRY; HINDLIMB; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REPERFUSION INJURY; STEM CELLS;

EID: 84899704798     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095720     Document Type: Article

References (43)

1. st.
2. Eltzschig HK, Eckle T (2011) Ischemia and reperfusion-from mechanism to translation. Nat Med 17(11): 1391-401.
3. Cogle CR, Guthrie SM, Sanders RC, Allen WL, Scott EW et al. (2003) An overview of stem cell research and regulatory issues. Mayo Clin Proc 78(8): 993-1003. (Pubitemid 36936130)
4. Castillo M, Liu K, Bonilla L, Rameshwar P (2007) The immune properties of mesenchymal stem cells. Int J Biomed Sci 3(2): 76-80.
5. Dazzi F, Lopes L, Weng L (2012) Mesenchmal stromal cells: a key player in 'innate tolerance'? Immunology 137(3): 206-13.
6. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD et al. (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99(10): 3838-43. (Pubitemid 34534559)
7. Le Blanc K, Pittenger M (2005) Mesenchymal stem cells: progress toward promise. Cytotherapy 7(1): 36-45. (Pubitemid 40542402)
8. Shi Y, Su J, Roberts AI, Shou P, Rabson AB et al. (2012) How mesenchymal stem cells interact with tissue immune responses. Trends Immunol 33(3): 136-43.
9. Gnecchi M, Zhang Z, Ni A, Dzau VJ (2008) Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 103(11): 1204-19.
10. Wang H, Wu M, Liu Y (2012) Are mesenchymal stem cells major sources of safe signals in immune system? Cell Immunol 272(2): 112-6.
11. Yang SH, Park MJ, Yoon IH, Kim SY, Hong SH et al. (2009) Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med 41(5): 315-24.
12. Salem HK, Thiemermann C (2010) Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 28(3): 585-96.
13. Baban B, Liu JY, Mozaffari MS (2012) Aryl hydrocarbon receptor agonist, leflunomide, protects the ischemic-reperfused kidney: role of Tregs and stem cells. Am J Physiol Regul Integr Comp Physiol 303(11): R1136-46.
14. Casado FL, Singh KP, Gasiewicz TA (2011) Aryl hydrocarbon receptor activation in hematopoietic stem/progenitor cells alters cell function and pathway-specific gene modulation reflecting changes in cellular trafficking and migration. Mol Pharmacoln 80(4): 673-82.
15. Ball HJ, Yuasa HJ, Austin CJ, Weiser S, Hunt NH (2009) Indoleamine 2,3- dioxygenase-2; a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol 41(3): 467-71.
16. Sugimoto H, Oda S, Otsuki T, Hino T, Yoshida T et al. (2006) Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci U S A 103(8): 2611-6.
17. Munn DH (2006) Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 18(2): 220-5.
18. Munn DH, Sharma MD, Hou D, Baban B, Lee JR et al. (2004) Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114(2): 280-90. (Pubitemid 39071633)
19. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D et al. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9(10): 1269-74. (Pubitemid 37279849)
20. Croitoru-Lamoury J, Lamoury FM, Caristo M, Suzuki K, Walker D et al. (2011) Interferon-gamma regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO). PLoS One 6(2): e14698.
21. Matysiak M, Stasiolek M, Orlowski W, Jurewicz A, Janczar S et al. (2008) Stem cells ameliorate EAE via an indoleamine 2,3-dioxygenase (IDO) mechanism. J Neuroimmunol 193(1-2): 12-23.
22. Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I et al. (2009) Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3- dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 27(4): 909-19.
23. Abramoff MD, Magelhaes PJ, Ram SJ (2004) Image Processing with ImageJ. Biophotonics International 11: 36-42.
24. Blaisdell FW (2002) The pathophysiology of skeletal muscle ischemia and the reperfusion syndrome: a review. Cardiovasc Surg 10(6): 620-30.
25. Boros P, Bromberg JS (2006) New cellular and molecular immune pathways in ischemia/reperfusion injury. Am J Transplant 6(4): 652-8. (Pubitemid 43345001)
26. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ et al. (2007) Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyltryptophan. Cancer Res 67(15): 7082-7. (Pubitemid 47206533)
27. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ et al. (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281(5380): 1191-3. (Pubitemid 28406294)
28. Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA et al. (2009) IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol 183(4): 2475-83.
29. Daubener W, Spors B, Hucke C, Adam R, Stins M et al. (2001) Restriction of Toxoplasma gondii growth in human brain microvascular endothelial cells by activation of indoleamine 2,3-dioxygenase. Infect Immun 69(10): 6527-31. (Pubitemid 32885221)
30. Hwu P, Du MX, Lapointe R, Do M, Taylor MW et al. (2000) Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 164(7): 3596-9. (Pubitemid 30169812)
31. Kaufmann SH (1993) Immunity to intracellular bacteria. Annu Rev Immunol 11: 129-63.
32. Mellor AL, Munn D, Chandler P, Keskin D, Johnson T et al. (2003) Tryptophan catabolism and T cell responses. Adv Exp Med Biol 527: 27-35. (Pubitemid 38197625)
33. Pfefferkorn ER (1984) Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci U S A 81(3): 908-12.
34. Sharma MD, Baban B, Chandler P, Hou DY, Singh N et al. (2007) Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 117(9): 2570-82. (Pubitemid 47494358)
35. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K et al. (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30(1): 42-8. (Pubitemid 34059216)
36. Giordano A, Galderisi U, Marino IR (2007) From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol 211(1): 27-35. (Pubitemid 46363893)
37. Baban B, Chandler P, McCool D, Marshall B, Munn DH et al. (2004) Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol 61(2): 67-77. (Pubitemid 38446980)
38. Baban B, Chandler PR, Johnson BA, 3rd, Huang L, Li M et al. (2011) Physiologic control of IDO competence in splenic dendritic cells. J Immunol 187(5): 2329-35.
39. Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ et al. (2005) Cutting edge: CpG oligonucleotides induce splenic CD19 + dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 175(9): 5601-5. (Pubitemid 41508038)
40. Lee JY, Giusti G, Wang H, Friedrich PF, Bishop AT et al. (2013) Functional evaluation in the rat sciatic nerve defect model: a comparison of the sciatic functional index, ankle angles, and isometric tetanic force. Plast Reconstr Surg 132(5): 1173-80.
41. Harizi H1, Gualde N (2006) Pivotal role of PGE2 and IL-10 in the crossregulation of dendritic cell-derived inflammatory mediators. Cell Mol Immunol 3(4): 271-7.
42. Milwid JM1, Ichimura T, Li M, Jiao Y, Lee J et al. (2012) Secreted factors from bone marrow stromal cells upregulate IL-10 and reverse acute kidney injury. Stem Cells Int. 2012: 392050.
43. Ming Li and Susumu Ikehara (2013) Immunomodulatory Properties and Therapeutic Application of Bone Marrow Derived-Mesenchymal Stem Cells. J Bone Marrow Res 1: 4.